To fund its attempts to convey MDMA therapy to industry, MAPS General public Advantage Company (PBC) — MAPS’ pharma subsidiary, which bifurcated in 2014 but did not acknowledge financial investment in return for fairness and will not secure the $70 million necessary to shift ahead — has morphed in to the for-income Lykos Therapeutics.MDMA was